Stock NXEN NEXIEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nexien BioPharma, Inc.

Equities

NXEN

US65343D1000

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 07:55:07 23/05/2024 pm IST 		5-day change 1st Jan Change
0.0164 USD -21.90% Intraday chart for Nexien BioPharma, Inc. +0.61% -36.68%
15/05 Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
20/02 Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 173.3 4.816 2.634 5.008 3.783 2.289
Enterprise Value (EV) 1 172.5 4.67 2.636 5.003 3.887 2.525
P/E ratio -131 x -1.07 x -0.99 x -2.67 x -5.77 x -6.16 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF -490 x -5.96 x -1.84 x -10.4 x -21.9 x 85.7 x
FCF Yield -0.2% -16.8% -54.2% -9.61% -4.56% 1.17%
Price to Book 148 x 18.1 x -417 x -365 x -32.2 x -9.08 x
Nbr of stocks (in thousands) 43,881 53,511 53,984 55,772 60,522 64,022
Reference price 2 3.950 0.0900 0.0488 0.0898 0.0625 0.0358
Announcement Date 28/09/18 30/09/19 28/09/20 12/10/21 28/09/22 28/09/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -1.283 -3.933 -2.637 -1.844 -0.564 -0.2826
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.283 -4.301 -2.672 -1.86 -0.6264 -0.3619
Net income 1 -1.283 -4.301 -2.672 -1.86 -0.6264 -0.3619
Net margin - - - - - -
EPS 2 -0.0301 -0.0843 -0.0495 -0.0336 -0.0108 -0.005805
Free Cash Flow 1 -0.3519 -0.7837 -1.429 -0.4806 -0.1774 0.0295
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 28/09/18 30/09/19 28/09/20 12/10/21 28/09/22 28/09/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0 - 0.1 0.24
Net Cash position 1 0.82 0.15 - 0.01 - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.35 -0.78 -1.43 -0.48 -0.18 0.03
ROE (net income / shareholders' equity) -147% -593% -2,059% 18,470% 954% 196%
ROA (Net income/ Total Assets) -78.4% -311% -988% -4,769% -470% -211%
Assets 1 1.637 1.385 0.2703 0.039 0.1333 0.1717
Book Value Per Share 2 0.0300 0 -0 -0 -0 -0
Cash Flow per Share 2 0.0200 0 0 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 28/09/18 30/09/19 28/09/20 12/10/21 28/09/22 28/09/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NEXIEN BIOPHARMA, INC. Stock Nexien BioPharma, Inc.
-36.68% 11.07L
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.65% 73TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.90% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.58% 33TCr
ABBVIE INC. Stock AbbVie Inc.
-0.25% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 24TCr
NOVARTIS AG Stock Novartis AG
+7.35% 21TCr
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 20TCr
AMGEN INC. Stock Amgen Inc.
+3.85% 16TCr
PFIZER, INC. Stock Pfizer, Inc.
-2.17% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NXEN Stock
  4. Financials Nexien BioPharma, Inc.